Angel Montero Carcaboso
Jefe de Grupo Senior
Research group
BS Pharm (1999) and PhD (2004) Universidad del País Vasco -Euskal Herriko Unibertsitatea. MBA (2003) UNED. Postdoctoral fellow in UBA (2004-2008) and Saint Jude Children's Research Hospital (2008-2010).
Dr Carcaboso holds a wide pharmaceutical background. He has performed multidisciplinary and translational work in the field of pediatric oncology. He has shown, together with his colleagues at SJD and his former institutions, success to develop innovative projects, even advanced therapies, for children with cancer. They have achieved clinical trials and international acknowledgement of their work.
The laboratory puts high effort to develop patient-derived tumor cell models and xenografts ("HSJD models"). Because this work is devoted to the families of children with cancer, the lab takes special care, as they request, of sharing all the resources generated mostly through their generosity. Consequently, the lab has shared cells and xenografts established at SJD with more than 60 research institutions worldwide. All these institutions focus in finding cures for children with cancer. These international collaborations position the laboratory among the most influential institutions in preclinical research of pediatric cancer in the world.
Selected publications
[1] H. Castillo-Ecija, C. Monterrubio, [...], A.M. Carcaboso, Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution, J Control Release 324 (2020) 440-449.
[2] G. Pascual-Pasto, [...], A.M. Carcaboso, Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01, Sci Transl Med 11(476) (2019).
[3] C. Monterrubio, [...], A.M. Carcaboso, Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8, J Control Release 255 (2017) 108-119.
[4] G. Pascual-Pasto, [...], A.M. Carcaboso, Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination, Cancer Lett 380(1) (2016) 10-19.
[5] C. Monterrubio, [...], A.M. Carcaboso, SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery, Biomaterials 79 (2016) 69-78.
Professional network profiles
Related websites
Publications en PubMed 
SJD Barcelona Children Hospital Last Publications
- Brown, Elizabeth J., Balaguer-Lluna, Leire, Cribbs, Adam P., Philpott, Martin, Campo, Leticia, Browne, Molly, Wong, Jong Fu, Oppermann, Udo, Carcaboso AM, Bullock, Alex N. and Farnie, Gillian PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo SCIENTIFIC REPORTS . 14(1): .
- Wiese M, Pohlmeier B, Kubiak K, El-Khouly FE, Sitte M, Carcaboso AM, Baugh JN, Perwein T, Nussbaumer G, Karremann M, Gielen GH, Salinas G and Kramm CM Boswellic acid formulations are not suitable for treatment of pediatric high-grade glioma due to tumor promoting potential Journal of Traditional and Complementary Medicine . 14(1): 101-108.
- Aschero MR, Ganiewich D, Lamas G, Restrepo-Perdomo CA, Ottaviani D, Zugbi S, Camarero S, Néspoli E, Cuadrado-Vilanova M, Pérez-Jaume S, Pascual-Pastó G, Sampor C, Grigorovski N, Salas B, Suñol M, Carcaboso AM, Mora J, de Dávila MTG, Doz F, Radvanyi F, Abramson DH, Llera AS, Schaiquevich PS, Lubieniecki F and Chantada G Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma PEDIATRIC BLOOD & CANCER . 71(1): .
Projects
- Project name:
- Ensayo clínico de seguridad y factibilidad de inmunoterapia celular: Células dendríticas autólogas pulsadas con un lisado de líneas tumorales alogénicas, asociadas con CART anti-IL13Ra2 en pacientes con tumor difuso intrínseco de tronco (DIPG) (fase Ib)
- Leader
- Andrés Morales La Madrid
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- ICI23/00063
- Starting - finishing date:
- 2024 - 2027
- Project name:
- Plataforma de Biobanco, Biomodelos e Impresión 3D Sant Joan de Déu como paradigma de excelencia en investigacion Pediatrica.
- Leader
- Cristina Jou Muñoz
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PT23/00002
- Starting - finishing date:
- 2024 - 2026
- Project name:
- Formación de doctores del programa nacional de formación de profesorado universitario 2022. Beneficiari: Núria Martínez
- Leader
- Angel Montero Carcaboso
- Funding entities:
- Ministerio De Universidades
- Code
- FPU22/00395
- Starting - finishing date:
- 2023 - 2027
News
-
New research facilities for studying children's cancer
New facilities have been opened for the children's oncology laboratory of the Institut de Recerca Sant Joan de Déu - SJD Barcelona Children's Hospital to celebrate 20 years of research. These laboratories are unique in their exclusive dedication to pediatric tumors and have over 50 researchers who focus on the study of more than ten developmental tumors.
-
Researchers at IRSJD develop a method to predict the efficacy of a potent nanomedicine in a severe childhood cancer
Researchers at IRSJD have developed a method that predicts the anticancer efficacy of nab-paclitaxel, a well-known nanomedicine, in mouse models, for treatment of Ewing sarcoma, a severe cancer affecting the bones and soft tissue of children and adolescents.
-
A nanomedicine to improve treatment of Ewing sarcoma
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.